DB&C Advisors LLC Purchases Shares of 37,182 Pfizer Inc. $PFE

DB&C Advisors LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE – Free Report) during the 4th quarter, Holdings Channel reports. The institutional investor bought 37,182 shares of the biopharmaceutical company’s stock, valued at approximately $926,000. Pfizer comprises approximately 1.2% of DB&C Advisors LLC’s holdings, making the stock its 25th largest holding.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Horizon Financial Services LLC raised its holdings in Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 645 shares in the last quarter. Godfrey Financial Associates Inc. acquired a new stake in Pfizer during the fourth quarter worth approximately $26,000. YANKCOM Partnership acquired a new stake in Pfizer during the fourth quarter worth approximately $28,000. HFM Investment Advisors LLC raised its holdings in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares in the last quarter. Finally, Darwin Wealth Management LLC acquired a new stake in Pfizer during the second quarter worth approximately $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Get Pfizer alerts:

Pfizer Stock Performance

NYSE:PFE opened at $26.04 on Friday. The firm’s fifty day moving average price is $26.62 and its 200 day moving average price is $26.29. Pfizer Inc. has a 1-year low of $23.11 and a 1-year high of $28.75. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The firm has a market cap of $148.43 billion, a price-to-earnings ratio of 19.88 and a beta of 0.34.

Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. During the same period last year, the firm posted $0.92 EPS. Pfizer’s quarterly revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. The ex-dividend date is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer signed a license agreement with Chai Discovery to gain early access to its AI drug-discovery platform, including the new Chai-3 model, which could improve antibody design and speed up research productivity. Pfizer signs licence agreement with Chai for AI drug discovery
• Positive Sentiment: Pfizer also reported fresh clinical-trial progress across its oncology pipeline, including updates on a lung cancer study, a bladder cancer combination trial with Astellas, and another advanced lung cancer combination program, signaling continued investment in future growth drivers. Pfizer’s New Lung Cancer Study Signals Fresh Oncology Upside for PFE Investors
• Positive Sentiment: Pfizer disclosed an update on a Phase 3 infant pneumococcal vaccine trial, suggesting continued momentum in its vaccine franchise and potential additional data catalysts ahead. Pfizer’s New Infant Pneumococcal Vaccine Trial: What Investors Should Watch
• Neutral Sentiment: Pfizer’s recent conference presentation and multiple earnings-related recap articles did not introduce a major new financial surprise, but they kept attention on post-earnings expectations and the company’s valuation. Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 Transcript
• Negative Sentiment: Some market commentary continues to highlight that PFE has been under pressure since its last earnings report, reflecting investor caution around near-term growth and execution. Why Is Pfizer (PFE) Down 4.5% Since Last Earnings Report?

Analyst Ratings Changes

PFE has been the topic of a number of research analyst reports. BMO Capital Markets reissued an “outperform” rating and set a $30.00 price objective on shares of Pfizer in a report on Monday, March 9th. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Barclays initiated coverage on shares of Pfizer in a report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price objective on the stock. HSBC raised their price objective on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. Finally, Bank of America lowered their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $28.82.

Check Out Our Latest Research Report on Pfizer

About Pfizer

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Featured Stories

• Five stocks we like better than Pfizer
• Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?
• IREN’s 800MW Bet Flips the AI Power Switch
• CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?
• Tesla’s EV Rebound Leaves Rivian and Lucid Facing a Tougher Investor Test

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.